Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04294667
Registration number
NCT04294667
Ethics application status
Date submitted
27/02/2020
Date registered
4/03/2020
Date last updated
21/06/2024
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Query!
Secondary ID [1]
0
0
2019-003406-27
Query!
Secondary ID [2]
0
0
SL0043
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PHOENYCS GO
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - DZP
Other interventions - Placebo
Experimental: Dapirolizumab pegol - Subjects will receive dapriolizumab pegol througout the Treatment Period.
Placebo comparator: Placebo - Subjects will receive placebo througout the Treatment Period.
Treatment: Drugs: DZP
Subjects will receive dapirolizumab pegol at prespecified time-points.
Other interventions: Placebo
Subjects will receive placebo at prespecified time-points.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Achievement of BICLA response at Week 48
Query!
Assessment method [1]
0
0
A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled:
1. British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and =1 new B.); and
2. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
3. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as =10mm increase on a 100mm visual analog scale
Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [1]
0
0
Achievement of BICLA response at Week 24
Query!
Assessment method [1]
0
0
A study participant is considered to be a BICLA responder if all of the following is fulfilled:
1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and =1 new B.); and
2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
3. No worsening in the PGA compared to Baseline Visit defined as =10mm increase on a 100mm visual analog scale
Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [2]
0
0
Achievement of BICLA response at Week 12
Query!
Assessment method [2]
0
0
A study participant is considered to be a BICLA responder if all of the following is fulfilled:
1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and =1 new B.); and
2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
3. No worsening in the PGA compared to Baseline Visit defined as =10mm increase on a 100mm visual analog scale
Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48
Query!
Assessment method [3]
0
0
BILAG severe flare is defined as a British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse and are qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
Query!
Timepoint [3]
0
0
During Treatment Period up to Week 48
Query!
Secondary outcome [4]
0
0
Achievement of LLDAS in =50% of post-Baseline visits through Week 48
Query!
Assessment method [4]
0
0
Low lupus disease activity state (LLDAS) is defined as:
* No significant disease activity as per SLEDAI-2K and BILAG 2004 (SLEDAI-2K score =4 with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, fever)
* No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
* PGA =33mm
* Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication =7.5mg per day
* Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Query!
Timepoint [4]
0
0
During Treatment Period up to Week 48
Query!
Secondary outcome [5]
0
0
Change from Baseline in SLEDAI-2K at Week 48
Query!
Assessment method [5]
0
0
The SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K; 30 days) measures disease activity. It is a global index and includes 24 clinical symptoms and laboratory variables that are weighted by the type of manifestation, but not by severity or dynamic of the individual item. The total score falls between 0 and 105, with higher scores representing increased disease activity.
Query!
Timepoint [5]
0
0
From Baseline (Day 1) to Week 48
Query!
Secondary outcome [6]
0
0
Achievement of BILAG improvement without worsening at Week 48
Query!
Assessment method [6]
0
0
BILAG 2004 improvement without worsening can be defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and =1 new B.
Query!
Timepoint [6]
0
0
Week 48
Query!
Secondary outcome [7]
0
0
Change from Baseline in PGA at Week 48
Query!
Assessment method [7]
0
0
Physician's Global Assessment of Disease (PGA) The Investigator will rate the overall status of the study participant.
Query!
Timepoint [7]
0
0
From Baseline (Day 1) to Week 48
Query!
Secondary outcome [8]
0
0
Achievement of SRI4 response at Week 48
Query!
Assessment method [8]
0
0
The Systemic Lupus Erythematosus Responder Index (SRI)-4 define responders as (ie, all criteria must be met):
* Reduction in SLEDAI-2K score of =4
* No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
* No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline
* No worsening in the PGA compared to study entry defined as =10mm increase on a 100mm visual analog scale
Query!
Timepoint [8]
0
0
Week 48
Query!
Secondary outcome [9]
0
0
Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48
Query!
Assessment method [9]
0
0
BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse and are qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse and are qualifying for the Grade B in any system (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG- 2004 index (Yee et al, 2010)
Query!
Timepoint [9]
0
0
During Treatment Period up to Week 48
Query!
Secondary outcome [10]
0
0
Time to severe BILAG Flare through Week 48
Query!
Assessment method [10]
0
0
BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse and are qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
Query!
Timepoint [10]
0
0
During Treatment Period up to Week 48
Query!
Secondary outcome [11]
0
0
Time to moderate/severe BILAG flare through Week 48
Query!
Assessment method [11]
0
0
BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse and are qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse and are qualifying for the Grade B in any system (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG- 2004 index (Yee et al, 2010)
Query!
Timepoint [11]
0
0
During Treatment Period up to Week 48
Query!
Secondary outcome [12]
0
0
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Query!
Assessment method [12]
0
0
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
Query!
Timepoint [12]
0
0
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Query!
Secondary outcome [13]
0
0
Percentage of participants with serious treatment-emergent adverse events during the study
Query!
Assessment method [13]
0
0
A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:
* Results in death
* Is life-threatening
* Requires in patient hospitalisation or prolongation of existing hospitalisation
* Is a congenital anomaly or birth defect
* Is an infection that requires treatment with parenteral antibiotics
* Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
Query!
Timepoint [13]
0
0
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Query!
Secondary outcome [14]
0
0
Percentage of participants with treatment-emergent adverse events of special interest during the study
Query!
Assessment method [14]
0
0
An adverse event of special interest is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.
Query!
Timepoint [14]
0
0
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Query!
Secondary outcome [15]
0
0
Percentage of participants with treatment-emergent adverse events of special monitoring during the study
Query!
Assessment method [15]
0
0
An adverse event of special monitoring is a product-specific AEs, adverse reactions, or safety topics considered as requiring special monitoring by UCB.
Query!
Timepoint [15]
0
0
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Query!
Eligibility
Key inclusion criteria
* Rescreening will be allowed once during the study in case there is new evidence for an inclusion criterion that was not fulfilled at the first screening or in case a study participant no longer meets an exclusion criterion or screening period exceeded the maximum duration due to delays in screening processes
* Study participant must be =16 years of age, unless restricted by local regulation, at the time of signing the Informed Consent form (ICF)
* Study participants who have moderate to severe disease activity due to either persisting active SLE or due to an acute worsening of SLE in the scope of frequent flaring/relapsing-remitting systemic lupus erythematosus (SLE) despite stable standard of care (SOC) medication defined as:
a. Diagnosed with SLE at least 24 weeks before the Screening Visit (Visit 1) study entry by a qualified physician b. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE c. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following: i) Evidence for anti-dsDNA (in central laboratory at Screening) ii) Either complement C3 < lower limit of normal (LLN) OR complement C4 <LLN OR elevated erythrocyte-bound complement C4d (where available) as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:
1. Anti-Smith (anti-Sm) antibodies (central laboratory) 2. Anti-Sjögren's syndrome antibody A (Anti-SSA) (Ro)/Anti-Sjögren's syndrome antibody B (anti-SSB) (La) autoantibodies (central laboratory) 3. Historic evidence for anti-dsDNA antibodies
d. Moderately to severely active defined as
* British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in =2 organ systems and/or a BILAG 2004 Grade A in =1 organ systems at Screening and Baseline Visit AND
* Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) =6 at Screening Visit AND
* SLEDAI-2K without labs =4 at Baseline Visit
e. Receiving the following SOC medication at stable dose:
* Antimalarial treatment in combination with corticosteroids and/or immunosuppressants or as stand-alone treatment if justified OR Treatment with corticosteroids and/or immunosuppressants if anti-malarial treatment is not possible
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life threatening condition
* Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies
* Study participant has a history of malignancy, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma
* Study participant has an increased risk for thromboembolic events due to an ongoing heart disease or due to a medical device, including but not limited to vascular graft, valvular heart disease, atrial fibrillation, or a heart rhythm disorder
* Study participant has evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection
* Study participant had a reactivated latent infection (example, cytomegalovirus, herpes simplex virus, or herpes zoster infection) or opportunistic infection (including but not limited to, pneumocystis, cytomegalovirus, or severe herpes zoster infection) within 12 weeks prior to the first study medication infusion (Visit 2), or is currently receiving suppressive therapy for an opportunistic infection
* Study participants who have received live/live attenuated vaccines within 6 weeks prior to the first study medication infusion
* Study participant has clinically significant active or latent infection
* Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE
* Study participant takes any protocol defined prohibited concomitant medication
* Study participant has previously been randomized within this study or participant has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP
* Study participant has participated in another study of an IMP within the previous 12 weeks or 5 half-lives of the investigational medicinal product (IMP) whatever is longer or is currently participating in another study of an IMP
* Study participant has chronic kidney failure stage 4, manifested by estimated glomerular filtration rate <30mL/min/1.73m^2, or serum creatinine >2.5 mg/dL, or participant has proteinuria >3 g/day, or protein: creatinine ratio >340 mg/mmol at the Screening Visit
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/08/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/09/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
321
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Sl0043 30020 - Parkville
Query!
Recruitment hospital [2]
0
0
Sl0043 30025 - St Albans
Query!
Recruitment postcode(s) [1]
0
0
- Parkville
Query!
Recruitment postcode(s) [2]
0
0
- St Albans
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Idaho
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nevada
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oklahoma
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Pennsylvania
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
West Virginia
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Capital Federal
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Ciudad Autonoma de Buenos Aire
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Mendoza
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Quilmes
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
San Juan
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Tucuman
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Graz
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Wien
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Bruxelles
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Liege
Query!
Country [35]
0
0
Bulgaria
Query!
State/province [35]
0
0
Plovdiv
Query!
Country [36]
0
0
Bulgaria
Query!
State/province [36]
0
0
Sofia
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Calgary
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Edmonton
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Rimouski
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Toronto
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Trois-rivieres
Query!
Country [42]
0
0
Chile
Query!
State/province [42]
0
0
Providencia, Santiago
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
Santiago de Chile
Query!
Country [44]
0
0
Chile
Query!
State/province [44]
0
0
Santiago
Query!
Country [45]
0
0
Colombia
Query!
State/province [45]
0
0
Barranquilla
Query!
Country [46]
0
0
Colombia
Query!
State/province [46]
0
0
Bogota
Query!
Country [47]
0
0
Colombia
Query!
State/province [47]
0
0
Bucaramanga
Query!
Country [48]
0
0
Colombia
Query!
State/province [48]
0
0
Chia
Query!
Country [49]
0
0
Colombia
Query!
State/province [49]
0
0
Medellín
Query!
Country [50]
0
0
Colombia
Query!
State/province [50]
0
0
Monteria
Query!
Country [51]
0
0
Czechia
Query!
State/province [51]
0
0
Praha 2
Query!
Country [52]
0
0
Denmark
Query!
State/province [52]
0
0
Odense
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Montpellier Cedex 5
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Paris Cedex 12
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Cologne
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Dessau
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Dresden
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Freiburg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Hanover
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Herne
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Leipzig
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Tübingen
Query!
Country [63]
0
0
Greece
Query!
State/province [63]
0
0
Athens
Query!
Country [64]
0
0
Greece
Query!
State/province [64]
0
0
Crete
Query!
Country [65]
0
0
Greece
Query!
State/province [65]
0
0
Haidari - Athens
Query!
Country [66]
0
0
Greece
Query!
State/province [66]
0
0
Larisa
Query!
Country [67]
0
0
Greece
Query!
State/province [67]
0
0
Thessaloniki
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Budapest
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Debrecen
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Gyula
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Szeged
Query!
Country [72]
0
0
Hungary
Query!
State/province [72]
0
0
Szekesfehervar
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Catania
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Ferrara
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Genova
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Milano
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Padova
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Roma
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Rozzano
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Busan
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Daejeon
Query!
Country [82]
0
0
Korea, Republic of
Query!
State/province [82]
0
0
Incheon
Query!
Country [83]
0
0
Korea, Republic of
Query!
State/province [83]
0
0
Seoul
Query!
Country [84]
0
0
Mexico
Query!
State/province [84]
0
0
Chihuahua
Query!
Country [85]
0
0
Mexico
Query!
State/province [85]
0
0
Cuernavaca
Query!
Country [86]
0
0
Mexico
Query!
State/province [86]
0
0
Guadalajara
Query!
Country [87]
0
0
Mexico
Query!
State/province [87]
0
0
Leon
Query!
Country [88]
0
0
Mexico
Query!
State/province [88]
0
0
Merida
Query!
Country [89]
0
0
Mexico
Query!
State/province [89]
0
0
Monterrey
Query!
Country [90]
0
0
Peru
Query!
State/province [90]
0
0
Arequipa
Query!
Country [91]
0
0
Peru
Query!
State/province [91]
0
0
Lima
Query!
Country [92]
0
0
Philippines
Query!
State/province [92]
0
0
Angeles
Query!
Country [93]
0
0
Philippines
Query!
State/province [93]
0
0
Davao
Query!
Country [94]
0
0
Philippines
Query!
State/province [94]
0
0
Makati
Query!
Country [95]
0
0
Philippines
Query!
State/province [95]
0
0
Manila
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Bialystok
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Bydgoszcz
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Katowice
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Krakow
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Lublin
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Nadarzyn
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Poznan
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Warszawa
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Wroclaw
Query!
Country [105]
0
0
Romania
Query!
State/province [105]
0
0
Bucharest
Query!
Country [106]
0
0
Romania
Query!
State/province [106]
0
0
Bucuresti
Query!
Country [107]
0
0
Romania
Query!
State/province [107]
0
0
Galati
Query!
Country [108]
0
0
Serbia
Query!
State/province [108]
0
0
Belgrade
Query!
Country [109]
0
0
Serbia
Query!
State/province [109]
0
0
Kragujevac
Query!
Country [110]
0
0
Serbia
Query!
State/province [110]
0
0
Novi Sad
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
A Coruna
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Barcelona
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Málaga
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Mérida
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Sabadell
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Sevilla
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Vigo
Query!
Country [118]
0
0
Taiwan
Query!
State/province [118]
0
0
Taichung City
Query!
Country [119]
0
0
Taiwan
Query!
State/province [119]
0
0
Taipei City
Query!
Country [120]
0
0
Taiwan
Query!
State/province [120]
0
0
Taipei
Query!
Country [121]
0
0
Taiwan
Query!
State/province [121]
0
0
Taoyuan City
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
UCB Biopharma SRL
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04294667
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
UCB Cares
Query!
Address
0
0
001 844 599 2273 (UCB)
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/study/NCT04294667
Download to PDF